In the pooled adjusted analysis, APOE ɛ 4 carriers had higher odds of cognitive decline (odds ratio [OR] = 1.46, 95% confidence interval [CI]: 1.29, 1.64) compared to noncarriers and the results were similar across cohorts (I2 = 19%, p = .29; Figure 1). Here, APOE is linked to Mental deterioration.